Spero Therapeutics, Inc. (NASDAQ:SPRO) Director Sells $53,990.82 in Stock

Spero Therapeutics, Inc. (NASDAQ:SPRO) Director Ankit Mahadevia sold 69,219 shares of the firm’s stock in a transaction dated Wednesday, February 5th. The shares were sold at an average price of $0.78, for a total transaction of $53,990.82. Following the completion of the sale, the director now owns 689,866 shares of the company’s stock, valued at approximately $538,095.48. The trade was a 9.12 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Spero Therapeutics Price Performance

Shares of NASDAQ SPRO traded up $0.12 on Wednesday, hitting $0.88. The company’s stock had a trading volume of 1,489,743 shares, compared to its average volume of 292,584. Spero Therapeutics, Inc. has a 12-month low of $0.74 and a 12-month high of $1.89. The company has a market capitalization of $47.81 million, a price-to-earnings ratio of 12.53 and a beta of 0.61. The stock has a 50 day moving average of $0.99 and a 200-day moving average of $1.19.

Analyst Ratings Changes

SPRO has been the subject of several recent analyst reports. TD Cowen reissued a “hold” rating on shares of Spero Therapeutics in a report on Monday, November 18th. Evercore ISI cut shares of Spero Therapeutics from an “outperform” rating to an “in-line” rating and set a $5.00 price target on the stock. in a research note on Friday, December 20th. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Spero Therapeutics in a report on Friday, November 15th. Finally, HC Wainwright reissued a “buy” rating and set a $5.00 price target on shares of Spero Therapeutics in a research note on Thursday, January 30th.

Spero Therapeutics Company Profile

Spero Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on identifying, developing, and commercializing novel treatments for multi-drug resistant (MDR) bacterial infections and rare diseases in the United States. The company’s product candidates include tebipenem pivoxil hydrobromide (HBr), an oral carbapenem-class antibiotic to treat complicated urinary tract infections, including pyelonephritis for adults; SPR206, an intravenous-administered antibiotic against MDR Gram-negative pathogens comprising carbapenem-resistant enterobacterales (CRE), acinetobacter baumannii, and pseudomonas aeruginosa, as well as negative bacterial infections in the hospital setting; and SPR720, a novel oral antibiotic agent for the treatment of non-tuberculous mycobacterial pulmonary disease.